Table 3.
Assessment of functional potency for MAB92 in primary cells.
| |
Agonist Ligand |
IC90 nM (SD) |
| Human NCI/ADR-RES ovarian epithelial cancer cell line | IL-36 α | 1.8 (0.3) |
| IL-36 β | Two.4 (1.1) | |
| IL-36 γ | One.5 (0.6) | |
| Human primary intestinal myofibroblasts | IL-36 α | 3.2 (1.6) |
| IL-36 β | Two.8 (1.1) | |
| IL-36 γ | Three.7 (3.5) | |
| Human primary keratinocytes | IL-36 α | 2.2 (0.1) |
| IL-36 β | One.9 (0.5) | |
| IL-36 γ | 0.7 (0.1) | |
| Human primary dermal fibroblasts | IL-36 α | 3.8 (1.9) |
| IL-36 β | Nine.0 (0.9) | |
| IL-36 γ | Sixteen (7.7) | |
| Cynomolgus monkey primary dermal fibroblasts | IL-36 α | |
| IL-36 β | >3000 | |
| IL-36 γ |